Literature DB >> 21601882

CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling.

Kumiko Hongo1, Junichiro Tanaka, Nelson H Tsuno, Kazushige Kawai, Takeshi Nishikawa, Yasutaka Shuno, Kazuhito Sasaki, Manabu Kaneko, Masaya Hiyoshi, Eiji Sunami, Joji Kitayama, Koki Takahashi, Hirokazu Nagawa.   

Abstract

BACKGROUND AND AIM: Recently, the cancer stem cells (CSCs) theory has been proposed, and CD133 has been suggested as a potential marker of CSCs in various cancer types. In the present study, we aimed evaluate CD133 as a potential marker of colorectal CSCs and, for this purpose, isolated CD133(+) and CD133(-) cells from a single colorectal cancer cell line, and compared their features, especially related to the tumor-forming and differentiation abilities, and the sensitivity to chemotherapy. METHODS AND
RESULTS: CD133(+) cells had higher in vivo tumor-forming ability than CD133(-) cells, and in culture, they progressively differentiated into CD133(-) cells, but not vice-versa. On the other hand, CD133(-) cells were more resistant to 5-fluorouracil (FU) treatment than CD133(+) cells, and it was found to be dependent on the higher expression of ß1-integrins, and consequently, higher ability to bind collagen. Disruption of the ß1-integrin function abrogated the chemoresistance.
CONCLUSION: From the present results, we concluded that colorectal cancer CD133(+) cells, although showing some features of CSCs, are not more resistant to 5-FU than CD133(-) cells. Therefore, definite conclusions can not be drawn yet, but it is strongly suggestive that CD133 should not be used as a single CSC marker of colorectal cancer.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21601882     DOI: 10.1016/j.jss.2011.03.076

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  15 in total

1.  ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.

Authors:  Lijun Ma; Ting Liu; Yiran Jin; Jun Wei; Yinxue Yang; Hongquan Zhang
Journal:  Tumour Biol       Date:  2016-07-23

Review 2.  Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives.

Authors:  Caterina Fanali; Donatella Lucchetti; Marisa Farina; Maddalena Corbi; Valerio Cufino; Achille Cittadini; Alessandro Sgambato
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 3.  CD133: a cancer stem cells marker, is used in colorectal cancers.

Authors:  Fei Ren; Wei-Qi Sheng; Xiang Du
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

4.  High-level β1-integrin expression in a subpopulation of highly tumorigenic oral cancer cells.

Authors:  Hsiang-Chun Lin; Chao-Liang Wu; Yuh-Ling Chen; Jehn-Shyun Huang; Tung-Yiu Wong; Kuo Yuan
Journal:  Clin Oral Investig       Date:  2013-08-25       Impact factor: 3.573

5.  Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells.

Authors:  Juanjuan Ou; Jia Deng; Xing Wei; Ganfeng Xie; Rongbin Zhou; Liqing Yu; Houjie Liang
Journal:  Stem Cell Res       Date:  2013-06-04       Impact factor: 2.020

6.  Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer.

Authors:  Kumiko Hongo; Shinsuke Kazama; Eiji Sunami; Nelson H Tsuno; Koki Takahashi; Hirokazu Nagawa; Joji Kitayama
Journal:  Med Oncol       Date:  2012-01-14       Impact factor: 3.064

7.  Sequential expression of putative stem cell markers in gastric carcinogenesis.

Authors:  T Wang; C W Ong; J Shi; S Srivastava; B Yan; C L Cheng; W P Yong; S L Chan; K G Yeoh; B Iacopetta; M Salto-Tellez
Journal:  Br J Cancer       Date:  2011-08-09       Impact factor: 7.640

8.  Analysis of the Correlation between CD133 Expression on Human Colorectal Adenocarcinoma Cells HT-29 and Their Resistance to Chemotherapeutic Drugs.

Authors:  I V Kholodenko; Ya S Kim; A M Gisina; A Yu Lupatov; R V Kholodenko; K N Yarygin
Journal:  Bull Exp Biol Med       Date:  2021-05-31       Impact factor: 0.804

9.  Response to stress in early tumor colonization modulates switching of CD133-positive and CD133-negative subpopulations in a human metastatic colon cancer cell line, SW620.

Authors:  Chih-Sin Hsu; Chien-Yi Tung; Chih-Yung Yang; Chi-Hung Lin
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy.

Authors:  Khalilullah Mia-Jan; So Young Jung; Ik-Yong Kim; Sung Soo Oh; EunHee Choi; Sei Jin Chang; Tae Young Kang; Mee-Yon Cho
Journal:  BMC Cancer       Date:  2013-03-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.